ArticleAmerican journal of translational research2022
Levosimendan improves postoperative heart function recovery and prognosis in patients with heart disease.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery.Journal of cardiovascular development and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown that levosimendan can reduce mortality and complications in patients undergoing cardiac surgery. The purpose of this study was to investigate the effect of levosimendan on the recovery of cardiac function, quality of life and prognosis in patients with heart disease after operation.
methodsFrom October 2017 to August 2019, 93 patients admitted to our hospital for cardiac surgery were retrospectively enrolled in this study. Fifty-three patients treated with levosimendan were included in the experimental group (EG) and 40 who did not receive levosimendan were recruited into the control group (CG). After operation, the length of ICU stay and hospitalization, mean arterial pressure, central venous pressure, heart rate, the changes of cardiac parameters (left ventricular end diastolic volume (LVEDV), end-systolic volume (LVESV), left ventricular ejection index (LVEF) and cardiac index (CI) at different time points), and the changes of high sensitive troponin I (hs-cTnI), creatine kinase isoenzyme (CK-MB) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were compared between the two groups. The stroke volume index (SVI), left ventricular stroke work index (LVSWI), systemic vascular resistance index (SVRI) and other hemodynamic indexes were also compared.
resultsThe length of ICU stay and hospitalization time in the EG were shorter than those in the CG. After treatment, MAP (mean arterial pressure), CVP (central venous pressure), HR (heart rate), LVEDV, LVESV, HS CTN, NT proBNP and SVRI in the EG were lower than those in the CG group, while LVEF, CI, SVI and LVSWI were higher than those in the CG. The quality of life of patients in the EG was better than that of those in the CG one month after treatment. Logistics regression analysis revealed that the use of levosimendan can reduce the risk of death.
conclusionLevosimendan can improve the cardiac function and prognosis of patients after cardiac surgery, which is worthy of clinical promotion.
Indexed as
Identifiers
35422928PMC8991159W4226270198What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.